A summary of the lessons that our industry learned from the COVID-19 pandemic, and have to incorporate as best practices in the next years future for all our new developments and also commercial practices. Transparency is the axial factor for healthy growth in the next decade.
The COVID-19 pandemic was a great booster for the pharma industry's innovation pipeline. At first glance, it could seem that clinical trial patients’ recruitment was delayed or exhibition batch production stopped for a time, but the R&D efforts and synergies between the public and private sectors worldwide will continue for many years as an important growth factor for the sector.
Without any doubt, things are very positive; cash flow speeds up, and new investments come to our sector.
I believe that new regulatory pathways will be created, making it easier for the population to afford the new medicines without increasing any safety risks.
Not very much; today's clinical research is very efficient.
In a very positive way, not only globalization but also a connection between the private and public sectors everywhere creates new opportunities for the development of pharma and medical practices.
The most significant new technology is by far the mRNA technology, now applied in COVID vaccines but with a lot of new applications in the future. The pandemic was a great test for this technology; hundreds of thousands of doses were applied worldwide in a very short period of time without major safety issues, which was very positive in every aspect.
Yes, it will definitely continue and increase.
The pressure for better medicines at affordable prices will not stop, and the pandemic will accelerate this process. Both the public sector as governments and social security players, as well as private patients at pharmacies, will actively ask for this policy.
Public health awareness will be a booster for our sector; more people are viewing their health as a big value that needs attention, so more patients will be in the doctor's office and later require more medicines from us. This process will be deeper in the next few years.
New digital technologies are quickly adapting in our industry: electronic batch records, paperless procedures, more data integrity risk assessment, electronic signatures, and e-CRFs are only a few examples that will be met in the near future in our pharma companies.
Time is always a factor that must be considered in the development of a new medicine or treatment. Sometimes we forget about this; we focus on efficacy and safety and sometimes forget the time factor. This will not be the case, in my opinion, in the next few years in our industry.
I believe that this will not happen very fast because there are still many factors, sometimes commercial competition, scientific grant contests, etc., that are not very easy to overcome and make data sharing more open and free.
Yes, it is a must—not better, a have-to. Our industry has to increase the transparency of all their operations, have a big scientific risk assessment, and show this to all key players, such as regulators, politicians, patient groups, medical associations, journalists, etc.